Health Care Deal News, August 18, 2014 - Private Equity Health Care Acquisitions Since 2008


Brought to you by

August 18, 2014 Issue:


Recent Health Care M&A Deals






PDI, Inc.

Cancer Test Portfolio

$8 million

Oncothyreon Inc.

Alpine Biosciences

$27 million



Allergan Inc.

Rights to LiRIS®

$67.5 million


U.S. Rights to

hydrocodone products

$100 million


Global License for Afrezza®

$150 million



Alvogen Buys Korean Dream Pharma

In yet another specialty pharma deal, privately held Alvogen Pharma US, Inc. of Pine Brook, New Jersey, acquired South Korea-based Dream Pharma for $187 million in cash. On completion, the new entity will become one of the largest generic pharmaceutical companies in South Korea. Alvogen’s stated ambition is to become one of the top five regional players in the Asia-Pac market. Dream has a portfolio of more than 100 products, and currently has a 35% share in the Korea obesity products market. The transaction is expected to close in the fourth quarter.  


Private Equity Health Care M&A

Health care companies and providers have long been targets for private equity firms. Since 2008, 267 acquisitions have been conducted by private equity groups, which represents just 4% of the combined total of 6,766 deals recorded and closed in that timeframe. PE deal-making activity has picked up annually since 2011, and will likely surpass 2013’s level of 55 transactions. There’s still plenty of time till 2015. 


PE Acquisitions in Health Care, since 2008

Year PE Deals Annual Total PE Share
2008 32 1,001 3%
2009 18 944 2%
2010 37 1,006 4%
2011 31 1,021 3%
2012 49 1,092 4%
2013 55 1,027 5%
2014* 45 675 7%

* = through July 31. Source: The Health Care M&A Information Source, August 2014


IPC The Hospitalist Company Moves into Connecticut 

IPC The Hospitalist Company (NASDAQ: IPCM), which acquires in hospital medicine and post-acute physician group practices, has acquired GeriCare, LLC, a post-acute medical group practice with operations throughout Connecticut. GeriCare estimates its patient encounters are approximately 42,500 on an annualized basis. Terms were not disclosed.


Tolero Pharmacetuicals Closes Series B Funding

Salt Lake City, Utah-based Tolero Pharmaceuticals, Inc., a clinical-stage biopharma that develops treatments for oncology and hematologic diseases, closed a $14.2 million Series B financing, led by Fred Alger Management Inc., and other institutional and individual investors. Proceeds will go toward the further development and commercialization of its lead program, alvocidib, in development for the treatment of acute myeloid leukemia. Phase 3 clinical trials are expected to begin in 2015. T.R. Winston & Company, LLC acted as exclusive placement agent to Tolero..........Click here for a free trial to The Health Care M&A Information Source and download the current issue today.



Sponsored Content:


7th CNS Partnering & Dealmaking, San Francisco, CA

CNS Partnering & Deal-Making Summit, September 18-19, in San Francisco. Networking and collaboration in biotechnology


The 2014 Hospital Acquisition Report - Free Webcast Offer!

There's no quicker way to get current on the hospital M&A market or review historic hospital M&A data. Learn all about today's hospital merger and acquisition market, not just what's covered in major media. Order by August 31st and receive a FREE webcast: Key Growth Sectors in the Health-Care Services M&A Market. Go to or call 800-248-1668 to order today.



Sign up for a free trial subscription to Health Care M&A News!

Be the first to know. Don't risk missing another day of this week's biggest health care M&A deals! Sign up here.


Around the Web in Health Care M&A...Click here to see more

Webcast Calendar...Click here to see more


Upcoming Investor Conferences - Seniors Housing and Health Care... Click here to see more


Previous Issues of Health Care Deal News...Click here to see more